Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
450 INR | +1.41% | +4.64% | +4.60% |
Apr. 25 | Transcript : Laurus Labs Limited, Q4 2024 Earnings Call, Apr 25, 2024 | |
Apr. 25 | Laurus Labs' Consolidated Profit Falls in Fiscal Q4 | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 126.38 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.60% | 2.87B | C- | ||
+34.00% | 664B | C+ | ||
+29.29% | 567B | B | ||
-7.75% | 354B | C+ | ||
+18.53% | 330B | B- | ||
+4.95% | 286B | C+ | ||
+13.79% | 234B | B+ | ||
+4.93% | 199B | B- | ||
-9.78% | 196B | A+ | ||
-4.89% | 148B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LAURUSLABS Stock
- Ratings Laurus Labs Limited